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Vomiting is a very common pregnancy associated symptom, but happens with a wide 
range of severity.  At its most severe form, vomiting of pregnancy causes dehydration, 
ketosis and severe weight loss, and this is termed hyperemesis gravidarum. If untreated, 
or badly treated, the condition can be fatal.  Typically admissions are prolonged and 
repeated even though highly effective therapy has been recognised for well over a 
decade. 
 
Given that hyperemesis gravidarum occurs with a very wide range of degrees of severity, a 
definition of “severe hyperemesis” is required.  Severe intractable vomiting which prevents 
eating and produces more than 5% weight loss in early pregnancy has been recommended 
as a practical definition (1).  This serves to emphasize an important aspect of the condition 
in that it prevents normal eating and malnutrition of mother and potentially of baby may 
occur. Women fulfilling this definition require expert, effective treatment.  However, the 
definition must not be applied rigidly. For instance, once a woman has suffered severe 
hyperemesis in one pregnancy, it is highly likely to occur with greater severity in a 
subsequent pregnancy, and the diagnostic criteria can be relaxed to allow earlier effective 
treatment.   
 
Clinical diagnosis of hyperemesis itself should present no particular problems.  Some text 
books incorrectly describe hyperemesis as a condition of continuous vomiting of onset in 
the first twenty weeks of pregnancy, but in practice there is a sudden onset of symptoms 
most often in the first six weeks, and always before eight weeks of gestation.  Severe 
vomiting of later onset is highly likely to have a different cause.  In approximately one third 
of women there will be a family history of severe vomiting in pregnancy affecting first 
degree family members.  The history of weight loss will be confirmed by the presence of 
wasting especially of leg muscles.  Abdominal discomfort on examination is that expected 
from severe prolonged vomiting of any cause. Should a doctor unwisely request thyroid 
function tests in a sick, vomiting person he or she will find that they are likely to be 
abnormal – the “sick euthyroid syndrome”. This still causes confusion, and non-
endocrinologists often are not aware that thyroid function tests are unreliable during any 
acute illness.  
 
A close review of the symptoms is helpful as a background to diagnosis.  Typically there is a 
very sudden onset of nausea between 4 and 6 weeks gestation, followed by vomiting which 
rapidly becomes intractable (2; 3).  There is no diurnal pattern to the vomiting, quite unlike 
even troublesome morning sickness.  Ptyalism is prominent in around half of all women.  
This apparent excess production of saliva relates to inhibition of the normal swallowing 
reflex, interrupting the usually subconscious swallowing of saliva.  It is worth noting that the 
consistent spitting out of saliva elicits little sympathy from medical and nursing staff, who 
often label the behaviour as some form of pseudo-vomiting.  The general lack of sympathy 
exhibited by healthcare staff not tuned into severe hyperemesis is in itself a helpful 
diagnostic feature.  This relates in part to the erroneous description in standard text books 
of hyperemesis as being a “psychological condition reflecting rejection of pregnancy”.  
Women who are overweight or obese before pregnancy are especially likely to have their 
malnutrition and weight loss disregarded, as they still have excess adiposity.  The lack of 
sympathy from health care staff also reflects a lack of awareness of the wide range of 
severity of hyperemesis in pregnancy. 
 
This lack of awareness of doctors, midwives and nurses of the existence of severe 
hyperemesis and the existence of effective therapy is reflected dramatically on patients’ 
websites.  Very graphic descriptions of lack of sympathy and even treatment by termination 
of pregnancy can be read on patients’ blogs on the internet.  The Hyperemesis Education 
and Research Foundation website is a good resource (www.helpher.org), although it suffers 
from the usual malady of patient- generated websites that all treatments ever suggested are 
listed, from copper bracelets through ginger biscuits to steroid therapy.  
 
Therapy for hyperemesis should follow normal sound lines of clinical management.  
Dehydration requires to be managed with rapid intravenous rehydration.  If vomiting has 
been preventing food intake for more than two weeks, then vitamin B1 (thiamine) 
replacement therapy is very important to avoid the possibility of Wernicke’s 
encephalopathy.  Thiamine, normally given in the U.K. as the intravenous preparation  
(Pabrinex) must be given before any carbohydrate is provided.  However once (and only 
once) thiamine has been replaced, there is a major advantage in provision of calories as 
intravenous 10% dextrose as each litre provides 400 kilocalories. This will allow suppression 
of ketone production. The repeated vomiting frequently causes significant heartburn, and 
this requires treatment with Ranitidine, initially intravenously and with oral follow up.  
Antiemetics can be prescribed, although there is only a small chance of useful response.  
One of the most important components of therapy is rarely discussed:  The symptoms of 
hyperemesis are markedly exacerbated by moving around, and also by smells of cooking.  
Bed rest will temporarily assist with suppressing the symptoms of hyperemesis.  In many 
women, a single admission with rehydration will suffice to control their condition.  The 
observation that vomiting recurs after discharge home is often interpreted as indicating 
some psychological problem at home rather than a normal reaction to resuming activities. 
However, if more than 5% weight loss has already occurred in comparison with reported 
pre-pregnancy weight, or if there have been previous similar admissions, then definitive 
therapy must be considered.   
 
For women in this defined group of severe hyperemesis, therapy with Prednisolone will be 
effective in all cases, if necessary preceded by intravenous hydrocortisone.  A full algorithm 
for therapy has been published (3) and this is reproduced as Figure 1. The usual starting 
dose would be hydrocortisone 50mg tid if intravenous therapy is required.  This would be 
continued until eating was able to be resumed, where after treatment with Prednisolone of 
20mg TID can be commenced.  Approximately one in five women will require a higher dose 
of steroid, and step wise increases to hydrocortisone 75mg then 100mg TID, or Prednisolone 
15mg or 20mg TID are necessary at approximately 48 hour intervals.  Care must be taken to 
achieve complete control of the hyperemesis prior to discharge, otherwise the journey 
home in the car is likely to precipitate recurrence of symptoms as discussed above.  
Subsequent prednisolone dosage depends upon the individual response, but in general the 
initial suppressive dose which is successful should be continued for two weeks, followed by 
a decrease of approximately 5mg per week with the proviso that if severe vomiting recurs 
the dose should be increased.  Awareness of the natural history of hyperemesis is 
important.  In 80% of women the hyperemesis will persist until 18-22 weeks (known as 
remitting hyperemesis) and during this time it has been observed that average daily 
prednisolone requirements are 15mg per day.  When the disease has run its course, the 
individual woman is never in doubt that the feeling of continuous nausea has lifted, and that 
steroid therapy can be rapidly tailed off and stopped.  Unfortunately this self-limiting form 
of hyperemesis is not universal, and around 20% of women have full term hyperemesis – 
which remits with dramatic suddenness as soon as the placenta is delivered. 
 
The decision to commence prednisolone therapy requires careful discussion with the 
individual patient.  The critical point is that steroid therapy has been used for severe asthma 
and inflammatory bowel disease in pregnancy for over sixty years and many studies have 
identified no evidence of harmful effect upon fetus (4-6).  The transplacental passage of 
prednisolone is only around 10% (7). On the other hand, untreated severe hyperemesis is 
likely to bring about a baby smaller than expected for dates and malnutrition during 
pregnancy is not without consequences.  Unfortunately potentially misleading information 
about steroid use and cleft lip or cleft palate is in circulation, relating to use of steroids 
anytime from before pregnancy to late pregnancy (8). One of the largest studies has found 
no association at all (Czeizel 1997). Another reported an increase in risk so small for the 
relevant period of exposure that it would not materially affect an individual decision (from 
1.0 in 400 to 1.3 in 400)(9). As an association has been demonstrated between any stressful 
event in pregnancy and cleft lip or palate by the same authors, it must be considered that 
the stress of any underlying illness for which steroid may be recommended might have 
more effect than treatment (10).   Given that the palate fuses before 8 weeks gestation this 
extremely small and possibly absent risk has to be put into perspective for each individual.  
Successful control of hyperemesis using prednisolone allows the achievement of absolutely 
normal growth for baby, and this is a major aim of the steroid therapy – to restore normal 
fetal nutrition (1).  
 
The potential side effects of steroids on the mother are identical to those seen out of 
pregnancy, with the exception of precipitation of diabetes.  No steroid associated diabetes 
has been observed in our Centre over nearly twenty years and approximately 200 steroid 
treated women with hyperemesis. This is likely to relate to two important features.  Firstly, 
the individual has experienced a period of starvation and weight loss, and liver fat levels will 
have been sharply decreased removing the main underlying factor permitting emergence of 
diabetes (11).  Secondly, hyperemesis is seen and managed considerably before the onset of 
pregnancy-associated glucose intolerance (24 weeks onwards).  Around 20% of women will 
experience a recurrence of their teenage acne, and this will persist for a month or two after 
the steroid therapy is withdrawn.  If steroid therapy is required throughout pregnancy, 
there is a possibility that bone density may be reduced.  The skeleton is in a state of major 
calcium flux by the end of pregnancy and the clinical effect of steroid therapy is not clear.  
However, bone scans carried out around three months after pregnancy in our Centre has 
not revealed any consistent tendency to persistent low bone mineral density.  All of these 
factors should be explained the individual woman so that she can make a well informed 
decision on whether or not to accept steroid therapy.  For most women with severe 
hyperemesis, the likelihood of complete control of symptoms and prevention of the 
disruption and upset of future hospital admissions is a major factor in determining 
acceptance. 
 
The recent illness of Kate Middleton has drawn media attention to this poorly understood, 
debilitating condition.  If managed properly, with provision of sound advice and 
multifaceted therapy as described above, the health of mother and baby can be 
dramatically improved.  From the perspective of the cash-strapped NHS, many bed days of 
unnecessary admissions are avoided.  All physicians should be aware of this important 
therapeutic possibility.   
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Legend to figure 
 
Newcastle guideline for management of steroid dose in severe hyperemesis (3). See full 
paper for discussion of overall management strategy. [NB PERMISSION TO REPRODUCE THIS 
WILL BE REQUIRED] 
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